|
Volumn 93, Issue 20, 2001, Pages 1517-1519
|
Rapamycin's resurrection: A new way to target the cancer cell cycle
a
a
NONE
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTIFUNGAL AGENT;
ANTINEOPLASTIC AGENT;
CYTOSTATIC AGENT;
IMMUNOSUPPRESSIVE AGENT;
RAPAMYCIN;
RAPAMYCIN DERIVATIVE;
TAMOXIFEN;
TEMSIROLIMUS;
TRASTUZUMAB;
UNCLASSIFIED DRUG;
BREAST CANCER;
CANCER CELL;
CANCER RESEARCH;
CELL CYCLE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DRUG MECHANISM;
HUMAN;
IMMUNE DEFICIENCY;
NOTE;
PHASE 1 CLINICAL TRIAL;
PHASE 2 CLINICAL TRIAL;
PRIORITY JOURNAL;
PROSTATE CANCER;
SOLID TUMOR;
TUMOR REGRESSION;
|
EID: 0035904293
PISSN: 00278874
EISSN: None
Source Type: Journal
DOI: 10.1093/jnci/93.20.1517 Document Type: Note |
Times cited : (76)
|
References (0)
|